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Catatonia has been described in children with intellectual disabilities (IDs). These are the first three published cases of catatonia in
adults older than 50 years of age with IDs. They were followed using the KANNER scale and, in one case, creatinine phosphokinase
(CPK) monitoring. Case 1 is a 67-year-old Caucasian who probably had been having intermittent episodes of undiagnosed catatonia
withdrawal for many years. His episodes of agitation and withdrawal behavior responded to lorazepam up to 8 mg/day. Case 2 is
a 63-year-old Caucasian male who had probably had undiagnosed catatonic episodes since age 25. An agitation episode that rated
88 on Part 2 of the KANNER scale ended within minutes after he received 1 mg of intramuscular lorazepam. He had no symptom
relapses for 4 years after getting stable oral lorazepam doses (3–8.5 mg/day). Case 3 is a 55-year-old African-American male with
severe ID and bradycardia (with a pacemaker). He had been “institutionalized” since age 22 and his undiagnosed catatonic episodes
appeared to have been intermittently present for at least the last ten years. As he became tolerant and experienced symptom relapse,
oral lorazepam was slowly increased (1.5–18 mg/day). Electroconvulsive therapy was ruled out due to his pacemaker.

1. Introduction
Although some psychiatrists think that catatonia has disappeared, it is becoming apparent that many psychiatrists
underdiagnose catatonia both inside [1] and outside the
United States [2, 3]. One of the contributing factors to this
underdiagnosis may be the ever-changing conceptualization
of catatonia (Table 1). Initially Kahlbaum described it in
1874 [4, 5] as a distinct entity, but Kraepelin mainly considered catatonia as a subtype of schizophrenia (dementia
praecox) [6]. After Kraepelin, many authors disagreed with
this opinion [7–10] but the Diagnostic and Statistical Manual
of Mental Disorders 3rd edition (DSM-III) [11] and the
revised third edition (DSM-III-R) [12] followed Kraepelin’s
hypothesis and included catatonia as a type of schizophrenia.
The influence of new publications [13–18] led the authors of
the DSM-IV [14] and its text revision, DSM-IV-TR [17], to

propose that catatonia consists of three entities: a type of
schizophrenia, a specifier for mood episodes, or a disorder
secondary to medical conditions. In the US, Taylor and Fink
were the main defenders of catatonia as a separate diagnostic
category [1, 13, 16, 18]. The DSM-5 eventually followed their
recommendations and categorized catatonia according to
three subtypes: (1) catatonia associated with another mental
disorder (catatonia specifier), (2) catatonic disorder due to
another medical condition, and (3) unspecified catatonia [19].
Not all experts agree with the DSM-5 decision [20].
The development of catatonia scales has contributed to an
improved definition of catatonic symptoms and how to assess
them. Table 2 describes the published catatonic scales [21–31],
with particular emphasis on the KANNER scale [31], which
was used to assess symptoms in the three patients described in
this report. In our experience, the KANNER scale is a good
choice for training residents to assess catatonic signs and is
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Table 1: Timeline of important events in the history of the diagnosis of catatonia.
Year

Event

1874

Kahlbaum described catatonia as a distinct entity.
Kraepelin described catatonia as a subtype of schizophrenia (dementia praecox), although he also stated it could
be found in mood disorders (manic-depressive illness).
Gjessing published an article in English summarizing his long experience with periodic catatonia, which
sometimes is a familial illness.
Gelenberg published an influential review which suggested that catatonia is a syndrome instead of being a form
of schizophrenia.
Abram and Taylor published their influential prospective study suggesting that the most frequent cause of
catatonia in their US hospital was mood disorders.
Leonhard’s textbook fifth edition was translated into English. In his view, catatonic symptoms can be found in
(1) motility psychoses (under cycloid psychoses); (2) familial periodic catatonia (under unsystematic
schizophrenias); and (3) nongenetic forms of catatonic schizophrenia (under systematic schizophrenias).

1919
1974
1976
1976
1979
1980

Reference
[4, 5]
[6]
[7]
[8]
[9]
[10]

DSM-III included catatonia as a type of schizophrenia.

[11]

1987

DSM-IIIR, as in DSM-III, continues to describe catatonia as a type of schizophrenia.

[12]

1990

Taylor published a comprehensive review on catatonia.

[1]

1991

First article by Fink and Taylor proposing a separate DSM category for catatonia.
DSM-IV included catatonia as a type of schizophrenia, a specifier for mood episode, and a disorder secondary
to a medical condition.
Peralta et al. studied 567 psychotic patients, identifying 45 catatonic patients, most of whom appear to fit in a
separate group, as Leonhard proposed in the motility psychoses.

[13]

1994
1997
2003
2004
2006
2013

[14]
[15]

Influential article by Taylor and Fink proposing that DSM create a category for catatonia.
DSM-IV-TR, as did DSM-IV, included catatonia as a type of schizophrenia, a specifier for mood episode, and a
disorder secondary to a medical condition.

[16]

Taylor and Fink published an influential book in catatonia.
DSM-5 described catatonia as separate syndrome.
DSM-5 required 3 of 12 catatonic symptoms to make the diagnosis of catatonia. The symptoms are
(1) stupor, (2) catalepsy, (3) waxy flexibility, (4) mutism, (5) negativism, (6) posturing, (7) mannerism, (8)
stereotypy, (9) agitation not influenced by external stimuli, (10) grimacing, (11) echolalia, and (12) echopraxia.

[18]

[17]

[19]

Table 2: Catatonia scales.
Review

List of catatonia scales

Description of
KANNER scale

Sienaert et al. [21] completed an excellent review of the published catatonia scales. Kirkhart et al. [22] presented
a more critical view of scales and diagnostic criteria.
(i) Rogers Catatonia Scale [23] and its modifications [24–26]
(ii) Bush-Francis Catatonia Rating Scale [27, 28]
(iii) Northoff Catatonia Rating Scale [29]
(iv) Braunig Catatonia Rating Scale [30]
(v) KANNER scale [31]
It was developed by Carroll et al. [31] as a “unifying instrument” that could be used across all neuropsychiatric
illnesses and consists of three parts.
(i) Part 1 is used to screen for the presence or absence of catatonia while Parts 2 and 3 are used to monitor
symptoms across time.
(ii) Part 1 is an 11-item screening mnemonic.
(iii) Part 2: if two or more signs are detected using Part 1 of the scale, Part 2 of the KANNER scale is used, which
consists of 18 questions that provide a score between 0 and 144. Nurses or other health providers who are in
close contact with the patient usually score Part 2.
(iv) Part 3 can be used by a psychiatrist to monitor catatonic signs.
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helpful for nurses (or other staff) who are quite familiar with
the patient to assess some of the core signs and symptoms for
long-term monitoring. Although it has not been systematically studied, several articles [32–34] verified our experience
that creatinine phosphokinase (CPK) monitoring is an additional objective way to monitor the severity of catatonia.
There is no agreement concerning the physiopathological
mechanisms that underlie the catatonic syndromes. Most
authors tend to agree that catatonic symptoms reflect frontal
lobe dysfunction [1, 18]. Dhossche et al. [35] provided a comprehensive review of the possible contribution of different
etiopathogenic mechanisms. Lauterbach et al. [33, 36] have
explored the contribution of different neurotransmitters.
In that sense, NMDA neurotransmission may be important, given that anti-NMDA-receptor encephalitis frequently
manifests catatonic symptoms [37]. Rosebush and Mazurek
[38] have proposed that “extreme fear” may be a common
contributing factor in all catatonic states.
Due to the severity and relative rarity of the condition,
it is not easy to conduct randomized clinical trials (RCTs)
in catatonic patients. There are only three RCTs published
regarding catatonia [39–41]. The first RCT was in acute
catatonia, where McCall et al. [39] randomized ten patients
with catatonic mutism to an intravenous (IV) amobarbital
solution and ten patients to IV saline. The respective initial
response rate was 6/10 and 0/10. Four of the saline nonresponders had a response when given amobarbital. The other two
were negative RCTs (one with lorazepam [40] and one with
amineptine [41]) in patients with schizophrenia and enduring
chronic catatonic symptoms. It is possible that chronic catatonic symptoms in schizophrenia may be different than the
typical cases of acute catatonia more frequently encountered
by clinicians in the US. There is general agreement in the
literature that there are two major types of treatments for
acute catatonia [42–44]: sedative agents in large dosages
(frequently in parenteral form) and electroconvulsive therapy
(ECT). Among sedatives, amobarbital was initially used, but
more recently benzodiazepines have been substituted [44].
Similarly, chemically induced seizures were first used in
patients who were catatonic, but this was rapidly replaced
by ECT, which is now considered the treatment of choice
when there is no response to benzodiazepines [42–44].
Sometimes catatonic patients appear to become tolerant to
benzodiazepines, but they may recover their benzodiazepine
response after ECT [45].
Classical authors [46, 47] described catatonia in children
with mental retardation (currently called intellectual disabilities [IDs]) and/or autism. Then in the 2000s [48–55] more
and more articles appeared reporting that catatonia can be
associated with IDs and autism in patients without an underlying diagnosis of schizophrenia or mood disorders, thus
leading to the inclusion in the DSM-5 of neurodevelopmental
disorders among the other mental disorders associated with
catatonia [19]. Review articles of the limited available information suggest that these catatonic patients with IDs may
also respond to benzodiazepines and/or ECT [55]. Clearly,
some cases of ID are associated with treatable conditions
[56]. It would stand to reason that correct identification and
treatment of an underlying neuropsychiatric illness (such as
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Wilson’s disease, anti-NMDA receptor encephalitis, multiple
sclerosis, PANDAS, lupus encephalopathy, HIV, and Fahr
disease) would also result in the treatment of catatonic symptoms associated with the underlying illness. Unfortunately,
the literature provides almost no information regarding treatment for the underlying neuropsychiatric conditions versus
“symptomatic treatment” with benzodiazepines and/or ECT
[57].
Recognizing catatonia as a unique clinical entity rather
than as a modifier for schizophrenia or mood disorders
allows for more rapid diagnosis in patients who have an
alternative underlying diagnosis (such as autism and/or an
ID) and allows clinicians to more accurately diagnose and
more rapidly treat such patients [50]. Overall, there is a
paucity of modern psychiatric literature describing catatonia
in individuals with an autism spectrum disorder or an ID,
and there are few published cases of catatonia in adults with
IDs, according to two systematic treatment reviews of the
literature [53, 55]. Mazzone et al. described eight published
cases in adults with no ages provided [53]. DeJong et al.
identified only six cases in adults with IDs older than 20 years
old and only one case older than 30 years of age (35 years old)
[55]. In a recent editorial, Dhossche [54] commented on the
lack of studies of older patients defined as >60 years of age.
This paper describes three cases of catatonia in older
male adults with IDs who were followed using the KANNER
scale [31] after benzodiazepine treatment. Mr. A was 67 years
old when diagnosed with catatonia but had been seen for
psychiatric symptoms since he was diagnosed with profound
mental retardation at age 6 months. After the catatonia
diagnosis and the lorazepam response, the mother reported
that the patient had been having intermittent episodes of
catatonia withdrawal for many years. Mr. B was 63 years old
when diagnosed with catatonia, but a chart review indicated
that episodes of catatonia were present since at least age 25.
Mr. C was 55 years old when diagnosed with catatonia. He
had been “institutionalized” since he was 22 years of age and
it was unclear when the catatonic episodes started, but they
appear to have been intermittently present over the last ten
years.

2. Case Presentations
2.1. Case 1
2.1.1. Prior History. Mr. A is a 67-year-old Caucasian male.
He had a history of severe jaundice at birth due to Rh
factor incompatibility and was diagnosed with kernicterus.
Currently, kernicterus is a controversial diagnosis, and some
prefer using the words “bilirubin-induced neurologic dysfunction” [58] to describe this syndrome. He was diagnosed
with “mental retardation” by the age of six months, did
not ever develop useful language, and was diagnosed with
profound mental retardation. He was admitted to an institution for children with IDs. He badly burned himself in a
cooking accident at the age of 34. Mr. A also had a history of
epilepsy but had been seizure-free since age 61. He had many
psychiatric admissions as an adult. He had been continuously
admitted to the same hospital for the last 17 years, prior to
being evaluated.
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The patient had multiple past psychiatric diagnoses, but
never catatonia. He had been treated with many psychiatric
medications from all the psychiatric classes (antidepressants,
anticonvulsants, antipsychotics, and stimulants) except for
long-term treatment with high doses of benzodiazepines.
Upon review of his chart, it was notable that Mr. A was
prescribed lorazepam 2 mg intramuscularly every 4 hours as
needed for “agitation.” His episodes of agitation at that time
were described as “flailing, kicking, and meal refusals.” After
administration of lorazepam, he would calm markedly and
would eat his meals. Interestingly, he did not appear sedated
after receiving lorazepam but rather was alert, oriented, and
engaged. He would remain calm for about three to five hours
after the dose of lorazepam and then another episode of
agitation would reoccur, often resulting in the administration
of a repeat dose of lorazepam. Two years after admission, his
as-needed medication was changed from lorazepam to chlorpromazine, and it appears that this was not overly effective.
After further chart review, he was noted to have episodes of
“deep depression” that were treated with citalopram. During
these episodes he would pull away from favored activities
that he seemed to enjoy and would withdraw, sulk, sleep
poorly, and stop eating. After the catatonia diagnosis, it was
considered possible that these episodes of “depression” might
actually be episodes of catatonic withdrawal and that his
flurries of intense and challenging behavior may be episodes
of catatonic excitement.
The description of the symptoms in the medical records
was very poor, so we cannot establish when the catatonic symptoms began in this patient. After the remarkable
improvement from high doses of lorazepam, which not only
helped with agitation but eliminated periods of catatonic
withdrawal, the mother stated that the patient has had
intermittent episodes of catatonia withdrawal for many years
until a high dose of lorazepam was started at 67 years of
age. In summary, the patient had many psychiatric symptoms
throughout his life and, according to his mother, continued to
have catatonic withdrawal episodes for many years until he
was treated with high-dose lorazepam.
2.1.2. Assessment. The senior author was asked to see the
patient to assess whether his uncontrollable agitation could
be explained by catatonia. At that time, the patient was taking
1800 mg/day of gabapentin for arthritic pain and 20 mg/day
of citalopram. The prior psychiatrist had started citalopram
at least 4 years prior. The current psychiatrists thought the
episodes of withdrawal were not a sign of depression but of
catatonia withdrawal.
At the time of assessment, Mr. A was having episodes of
agitation that were irregular in frequency and were occurring
about two times per week. Approximately half of the time
no trigger could be identified for the behaviors; they would
last from minutes to a full day. When his episodes were very
severe, it was difficult to hold the patient, and he would
require up to four adult staff to hold his extremities to prevent
injury. He was also described as having abnormal posturing
and progressive sequences of arm postures such as holding
his elbow at a 90-degree angle. Mr. A exhibited sequences of
movements in his arms and legs, such as hitting his shin with
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his heel repetitively. Such movements would increase with
agitation.
On the initial exam performed by the senior author, he
was nonverbal and did not follow simple commands. He was
reclining in his wheelchair with his back arched. His left
arm maintained a folded position behind his head and his
chair for five to ten minutes. His right arm was positioned
in front of him and placed at a 90-degree angle, and he
held it there for several seconds. Most of the time he did
not demonstrate stiffness or resistance when his arms were
moved; however, occasionally, he showed resistance that was
proportional to the efforts to move him, consistent with
paratonia. He also had features compatible with a generalized
tremor that was consistent with a cerebellar lesion (which was
thought to correlate with his diagnosis of kernicterus). He
also had severe dyskinetic movements in his face and lower
extremities, possibly secondary to previous antipsychotic use
or to the basal ganglia damage associated with kernicterus.
He had no dystonia, nor chorea or athetoid movements.
It was determined that he met the following eight out
of the twelve criteria for catatonia: stupor, waxy flexibility,
mutism, negativism, posturing, mannerism, stereotypy, and
agitation not influenced by external stimuli. He was diagnosed using the DSM-IV-TR [7] as having Catatonic Disorder
due to a General Medical Condition (kernicterus) given that,
at that time, the DSM-IV-TR did not allow a diagnosis of
catatonia associated with ID. If the DSM-5 had been in use,
he would have been diagnosed with catatonia associated
with a neurodevelopmental disorder. He was also diagnosed
with two noncatatonic abnormal movements: (1) generalized
tremor that was consistent with a cerebellar tremor and
(2) dyskinesia secondary to basal ganglia damage from
kernicterus versus tardive dyskinesia secondary to previous
antipsychotic treatment.
2.1.3. Follow-Up. For treatment, he was started on scheduled
oral lorazepam 1 mg/day (0.5 mg twice a day), which was
increased up to 4.5 mg/day (1.5 mg three times a day) over
a period of two months and then eventually increased to
8 mg/day over the subsequent 12 months. He showed marked
improvement, particularly in his posturing and stereotypy,
on the KANNER scale. Additionally, it is also interesting to
note that, as with most other patients with catatonia, he did
not have any symptoms of lethargy or respiratory depression
after lorazepam administration, even after increasing his daily
dose to 8 mg. The treatment with lorazepam helped him to
have some of the best years of his late life until age 72, when
he developed aspiration pneumonia and then was transferred
to a nursing home.
One year after the assessment, when the patient was doing
well on lorazepam, a slow taper of citalopram was started and
then it was discontinued completely. In summary, citalopram
did not prevent episodes of catatonia withdrawal and its
discontinuation did not bring them back.
2.2. Case 2
2.2.1. Prior History. Mr. B is a 63-year-old Caucasian male
with a history of an ID and epilepsy; he has lived in a group
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home setting since he was 20 years old. A chart review showed
that Mr. B had previously been able to independently perform
many activities of daily living until the fifth or sixth grade.
He was noted to have had gradual neurological deterioration
from age 13 until age 17, with impaired speech, loss of the
ability to walk independently, and a change in his seizure
pattern. His intelligence quotient (IQ) was estimated to be
around 30 at that time.
When he was 25 years old, Mr. B was noted to have
periods of hostility, agitation, and aggression for which he
was prescribed sodium amobarbital intramuscular injection
as needed and oral thioridazine 300 mg/day. He was reported
to engage in property destruction such as tearing linens,
taking light fixtures and air conditioning units off of the wall,
throwing filters on the floor, taking all the drawers out of his
dresser and emptying the contents on the floor, turning over
furniture, and lifting his bed high enough that the mattress
would fall off. Some of these episodes were reported to occur
while he was withdrawn, quiet, and sullen, with poor eye
contact, psychomotor retardation, hypersomnia, decreased
appetite, low energy level, low interest level, and lack of
motivation.
When he was 33 years old, he was found with a toothpick
pushed into his genitalia that caused bleeding. At that
time, Mr. B was on mesoridazine, orally 75 mg/day, and
benztropine, orally 4 mg/day. When he was 38 years old, he
was admitted for the first time to a psychiatric hospital for
evaluation. At that time, he was found unclothed on the
sun deck of the group home in what appeared to be an
attempt to jump off the brick railing on the third floor. He
also was noted to be increasingly withdrawn, staying mostly
in bed and refusing to get up, eat, or take his medications.
He would stay under his bed for days, refusing to come
out of his room. Mr. B was started on carbamazepine and
was discharged back to his group home after a month-long
hospitalization. At age 41, he was started on doxepin for
“recurrent destructive attempts.” The following year, he was
evaluated by a psychological consultant after increasingly
unusual and bizarre behavior. His speech was marked by
delusional themes concerning “the cross” and being crucified.
He was also noted to have periods of “posturing and waxy
flexibility.” He was described as noncommunicative and rigid,
holding his arms up in the air for long periods of time.
He also had periods of staring off into space or appearing
distracted and not reality-based. Mr. B would also refuse to
talk, eat, take his medications, or participate in daily hygiene
and grooming. At that time his diagnosis was changed to
schizoaffective disorder. Over the next ten years he was tried
on multiple different medications including haloperidol,
risperidone, venlafaxine, and paroxetine for psychosis and
mood lability but continued to demonstrate episodes of
withdrawal, abnormal posturing that the staff would call
“statue man,” and social isolation, followed by periods of
intense agitation with intermittent self-injurious behaviors
and aggression towards staff.
Seven months prior to evaluation, Mr. B had an episode of
agitation that was rated by the staff using the KANNER scale
[31] and was given a score of 88 for Part 2. At that time, he was
taking haloperidol, aripiprazole, lamotrigine, and valproic
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acid. The episode of agitation lasted about ten hours and
ended within minutes after he received an intramuscular
injection of lorazepam 1 mg (after two previous 0.5 mg doses
of oral haloperidol that did not appear to work). During this
episode, he was noted to be lying in the middle of the living
area naked, trying to bite and kick staff and scratching his
shoulder, and he had defecated and smeared feces in his bed,
was constantly moving himself off of the safety mats, and
was pounding his feet in a rhythmic motion on the floor and
was also refusing to eat. Additionally, Mr. B was noted to
have a “general blank stare on his face” with pursed lips and
squinted eyes and tense facial muscles. He required four staff
members to provide him with adequate hydration, nutrition,
and medications.
Over the next seven months, Mr. B had at least five
milder episodes of similar behavior, all of which showed
improvement in behavior after intramuscular injections of
lorazepam. Seven days prior to evaluation, he was started
on oral lorazepam 3 mg/day (1 mg three times daily). This
resulted in a six-week period free from such episodes until
he had an episode where he was found to be lying on the
floor, mute, and uncooperative. His repeat KANNER score
was rated at 46 for Part 2.
2.2.2. Assessment. A psychiatric consultation with the senior
author was requested regarding the frequent episodes of
agitation that were not controlled with his prior medication
regimen. The treating psychiatrist could not wait one week
for the evaluation and had started lorazepam. He requested
the consult to have his diagnosis of catatonia verified and
the chronic treatment with lorazepam approved. After seven
days on 3 mg/day of lorazepam, the patient no longer had
any catatonic signs. It was determined that during the prior
seven months he had met the following eight out of the twelve
criteria for catatonia: stupor, mutism, negativism, posturing,
mannerism, stereotypy, agitation not influenced by external
stimuli, and grimacing. If the DSM-5 had been available at
that time, he would have met criteria for catatonia associated
with a neurodevelopmental disorder. The patient had no
history of depressive or manic episodes and no history of
specific schizophrenia symptoms such as bizarre delusions
or the typical auditory hallucinations. Additionally, similar to
the patient in the previous case, this patient also was noted to
have a generalized tremor in his trunk, head, and arms and
was diagnosed with a cerebellar tremor.
2.2.3. Follow-Up. Mr. B had no relapse in catatonic symptoms
for four years after getting stable doses of lorazepam up to
8.5 mg/day.
2.3. Case 3
2.3.1. Prior History. Mr. C was a 55-year-old AfricanAmerican male born in a neighboring state. He and his
brothers were raised by their uncle and aunt. According to the
records, his father and mother did have limited education and
possibly were mentally retarded but, according to the family
report, his parents never had any psychiatric admissions. Mr.
C. had two brothers: one possibly had mental retardation and
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the other was definitively diagnosed with mental retardation
and had multiple admissions to our state psychiatric hospitals. According to the records, the patient was malnourished
when he was a baby. He did not learn to talk until age 7 when
he was diagnosed with mental retardation. His first intelligence quotient (IQ) was 41 at age 8. At age 22, he had his first
psychiatric admission due to aggressive behavior and carried
the diagnosis of severe mental retardation. Since that time,
he had been “institutionalized” and spent most of his time
in hospitals for adults with ID with occasional admissions to
psychiatric hospitals. According to the records available, he
had taken different antipsychotics throughout his life since
he was 15 years of age, but there was no clear description
of delusions and hallucinations. The antipsychotic appears
to have been prescribed to control his behavior, including
inappropriate sexual behavior. He had also been tried for
several months on lithium and carbamazepine, which appear
to have been added to augment his antipsychotic medications
in an effort to control his aggressive behavior. At 36 years
of age, he was taken to an emergency room for syncope,
and an abnormal value of CPK of 415 was described, but the
cause could not be identified. There was no description of
the behavior at that time to verify or rule out catatonia, and
the abnormal CPK was not followed up. Over many years,
episodes of unprovoked agitation, sometimes with violence
toward others, were described; however, the description was
very poor, and it was impossible to retrospectively determine
if they were associated with catatonia or not. At the time of
the assessment, he had resided at a hospital for adults with
IDs for ten years, and his diagnoses were psychotic disorder
not otherwise specified, bradycardia (with a pacemaker),
and severe mental retardation. The patient had never been
diagnosed with catatonia, but once some of the behaviors
were identified as catatonic, the staff described these behaviors as having been intermittently present for the last ten
years.
2.3.2. Assessment. At the time of initial evaluation, he demonstrated catatonic symptoms such as posturing, mutism,
stripping, freezing, posing, mild immobility, fixed staring,
grimacing, hitting and rubbing and scratching his bottom to
the point of injury, and twisting paper [31]. These behaviors
seemed to be stereotypic in nature and did not respond to
redirection. He had no other abnormal movements. He had
no hallucinations or delusions. Moreover, hallucinations and
delusions were not present in the year that the senior author
followed Mr. C and were not described by the hospital staff
who had known him for years.
It was determined that during the assessment and year
of follow-up he met the following eight out of the twelve
criteria for catatonia: stupor, mutism, negativism, posturing,
mannerism, stereotypy, agitation not influenced by external
stimuli, and grimacing. Other catatonic symptoms included
in the KANNER scale [31] that were present with catatonic
worsening were refusal to eat or drink and nudism. If the
DSM-5 had been available at that time, he would have met
criteria for catatonia associated with a neurodevelopmental
disorder. The patient had no other abnormal movements
besides those associated with catatonia.
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2.3.3. Follow-Up. Mr. C was started on oral lorazepam,
3 mg/day, and his CPK level at that time was 992 (Table 1),
but the lorazepam treatment was initially intermittent. He
was followed up for one year for treatment of catatonia with
lorazepam and required increasingly higher doses over the
course of the year, likely secondary to developing tolerance
to the medication. His behavior, CPK, and KANNER scores
were monitored. During this time, he was also taking olanzapine 20–25 mg/day. Lorazepam became a standard dose
of 1.5 mg/day on day 129 and then increased to 3 mg/day
on day 137, to 9 mg/day on day 157, to 12 mg/day on day
199, and to 18 mg/day on day 221 (Table 1). Generally, the
patient’s behavior would improve for a few days to weeks after
increasing his daily dose of lorazepam; however, he would
quickly become tolerant of the medication and would have a
relapse in symptoms. Furthermore, at times, it was difficult to
determine whether his aggressive behaviors were behavioral
in nature or were secondary to an underlying etiology such as
catatonia.
Despite using increasing doses of lorazepam, the catatonic behavior appeared to become partly tolerant to
lorazepam. We have prior experience with patients recovering benzodiazepine response after ECT, which has been
described by Petridis et al. [45]. Treatment with ECT was
seriously considered when catatonic symptoms including
ambitendency [27] and a specific stereotype (see footnotes
1 and 2, Table 3) increased at the same time that there were
increases in aggressive behavior and CPK rose to the 1400s.
Due to the presence of a pacemaker, ECT was excluded as
a treatment option by the only available hospital providing
ECT in the area. It should also be noted that, despite these
high benzodiazepine doses, he did not become sedated or
have any symptoms of respiratory suppression.

3. Discussion
The underdiagnosis of catatonia appears to be a major
problem [1–3]. In the last 15 years, it has become clear
that underdiagnosis of catatonia in children with IDs is
also a problem [48–55]. In a recent editorial, Dhossche [54]
commented on the lack of studies of older patients, defined
as >60 years of age. In the three adults with IDs presented in
this case series, the diagnosis of catatonia had been missed
for many years. Mr. A, who was 67 years old, probably had
intermittent episodes of catatonia withdrawal for many years.
Mr. B, who was 63 years old, had definitively had episodes
of catatonia since age 25. Mr. C, who was 55 years old, had
catatonic episodes intermittently present for at least ten years.
He had a high CPK value 19 years earlier, that is, at the age of
36 years, that may have been explained by catatonia.
The above cases demonstrate the importance of elucidating whether symptoms of “agitation” in adult patients
with IDs are behavioral in nature or catatonia secondary
to an underlying neurodevelopmental disability. In patients
with IDs and long history of multiple treatments, such as
these patients, placebo responses are unlikely; therefore, it is
doubtful that the lorazepam response could be explained by
a placebo response. As illustrated in Cases 1 and 2, once the
correct diagnosis is identified and appropriate treatment is
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Table 3: Case 3. Treatment, CPK, and catatonic symptoms.

Day Olanzapine mg/day Lorazepam mg/day
1
30
31
108
129
135
137
157
191
198
199
217
221
239
242
246
248
253
262
270
273
280
288
294
302
308
316
331
345
352

20
20
20
20
20
20
20
20
20
20
20
20
20
20
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25

3
3
0
0
1.5
1.5
3
9
9
9
12
12
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18

CPK IU/L
(range 24–204)
992

KANNER scale
Total score Mutism
92

4

86

2

Behaviors

Stereotypies1 and ambitendency2

262

Improvement3 and ↑ social interactions
692
776
600
801
442
682
408
416
408
721
441
379
332
346
538
805
375
426
835
1202
1493
1460

76

2

↑ aggressive behavior and stereotypies1
Improvement

58

2

Worsening, running away from house

72

6
↑ aggression, stereotypies1 , and ambitendency2

1

Stereotypies: the most characteristic stereotype associated with catatonic symptoms was rubbing and scratching his bottom to the point of irritating the skin.
Ambitendency: the patient appeared motorically stuck in indecisive, hesitant movements [27]. The patient would go back and forth from the shower and get
dressed and undressed.
3
The patient was described as the “best ever” by staff.
2

initiated, the improvement can be dramatic and long-lasting.
It should also be noted that all of the above patients were
given increasingly higher doses of lorazepam. Despite these
seemingly high doses (up to 18 mg/day in Case 3), none of
the patients displayed symptoms of sedation or respiratory
distress and typically were more alert and interactive after
the administration of the medication. Case 3 is an example
of the fact that catatonic patients can become tolerant to high
doses of benzodiazepines. Some of these tolerant patients
may recover a response to benzodiazepine after ECT [45].
The patient discussed in Case 3 was very challenging,
due to the consistent reemergence of catatonic symptoms
as he developed tolerance to lorazepam. Given his complex
behavioral symptoms, CPK was used as an indicator that

his symptoms were not volitional but were likely secondary
to an underlying biological dysfunction (likely catatonia).
Although it was not an exact linear correlation, his elevated
CPK level corresponded to worsening symptoms of catatonia.
Furthermore, his lowest CPK levels were associated with
his lowest KANNER scores, when the patient showed good
response to 9 mg/day of lorazepam (Table 3).
It is possible that the KANNER scale does not fully reflect
the overall severity of the patient’s current state of health.
The scale is not weighted for symptoms that could be lifethreatening (i.e., not eating or drinking, etc.); therefore, the
total KANNER score should be interpreted carefully and
the patient’s overall state of health should be considered
when determining treatment. Table 3 shows that the item
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“mutism,” which was elevated at the beginning of the followup, decreased while the patient was responding to lorazepam
doses of 9–12 mg/day but later worsened, which led to an
increased dosage of up to 18 mg/day. Future studies need
to consider the possibility that CPK could be used as a
more objective measure of severity of illness and could be
used in conjunction with the KANNER scale. This would
be especially helpful in patients with IDs or other neurodevelopmental disabilities who may have baseline behavioral
problems that make assessing catatonia difficult. Lastly, it is
possible that CPK reflects some catatonic symptoms more
than others. Our experience is that the highest CPK elevations in catatonic patients occur with severe exacerbations
of hyperactive symptoms of catatonia (i.e., excitement and
combativeness) or of immobility with severe stiffness. Future
studies need to better establish the relationship of CPK and
catatonic symptoms.

4. Conclusion
To date, there is no literature discussing older adult patients
with IDs and catatonia. This is likely secondary to the
underidentification of catatonia as well as the complexity of
treating patients with IDs. With the change in the DSM-5
diagnostic criteria, hopefully awareness of catatonia as an
entity separate from psychosis will increase awareness of
catatonia in adults with IDs. Better tools are needed to help
monitor and treat these patients.
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